Switzerland · Delayed Price · Currency is CHF Galenica AG Earnings Call Transcripts
Fiscal Year 2025
-
Strong sales and EBIT growth in 2025 were driven by organic expansion, acquisitions, and efficiency gains, with a positive outlook for 2026 and beyond. Strategic milestones included the Labor Team acquisition, ERP upgrades, and a focus on profitable segments.
-
Transformation is driven by culture, digitalization, and staff engagement, with major investments in logistics, diagnostics, and omni-channel pharmacy services. Growth is targeted through innovation, acquisitions, and efficiency, while regulatory changes and market trends are actively managed.
-
Sales grew 5% in H1 2025, with improved profitability and cash flow. Guidance for 2025 is confirmed, with EBIT growth outlook raised to 7%-9% due to one-off effects. The acquisition of Labora Team expands into diagnostics, while market and regulatory pressures remain.
Fiscal Year 2024
-
Solid H1 2024 growth outpaced the market despite weather and IT challenges, with strong performance in products, brands, and local pharmacies. Guidance for 2024 is confirmed, expecting stronger H2 growth, while ERP rollout and high generic substitution rates remain key headwinds.